Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
138
datasets available to search
ShareScore release 0.7.1
Dataset results
138 results for “viral hepatitis”
Efficacy of Vitamin D on Top of Pegylated Interferon and Ribavirin in Patients With Chronic Viral Hepatitis C Null-Responders
ClinicalTrials.gov study NCT01226446. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Improvement of Portal Hypertension During Viral Suppression in Patients With Hepatitis Delta (IMPHROVE-D)
ClinicalTrials.gov study NCT04863703. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Long-term Outcomes of Anti-viral Therapies in Patients With Chronic Viral Hepatitis B
ClinicalTrials.gov study NCT04896255. IPD Sharing: Not stated. Countries: 1. Publications: 15.
Acceptability of Simultaneous Screening for Viral Hepatitis B, C and HIV Among Drug Users in Non-conventional Structures
ClinicalTrials.gov study NCT05361603. IPD Sharing: NO. Countries: 1. Publications: 9.
Hepatitis B Virus (HBV) Viral Suppression by Entecavir in Adefovir Partial Responders
ClinicalTrials.gov study NCT00704106. IPD Sharing: Not stated. Countries: 1. Publications: 15.
The Kentucky Viral Hepatitis Treatment Study
ClinicalTrials.gov study NCT03949764. IPD Sharing: YES. Countries: 1. Publications: 1.
Evaluation of Hepatitis C Viral Load Quantification on DBS in Vietnam
ClinicalTrials.gov study NCT03670251. IPD Sharing: NO. Countries: 1. Publications: 4.
Real World Study of Chronic Viral Hepatitis
ClinicalTrials.gov study NCT04025944. IPD Sharing: UNDECIDED. Countries: 1. Publications: 2.
Long-term Follow Up of Viral Hepatitis in Uremic Patients in Taiwan
ClinicalTrials.gov study NCT01766895. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Study of Safety, Tolerability, and Anti-Viral Effect of Locteron Compared to PEG-Intron in Patients With Chronic Hepatitis C
ClinicalTrials.gov study NCT00593151. IPD Sharing: Not stated. Countries: 1. Publications: 0.
12 Week Study of Anti-Viral Effect of Oral UT-231B in Non-cirrhotic Hepatitis C Patients who have Failed Interferon-based Therapy.
ClinicalTrials.gov study NCT00069511. IPD Sharing: Not stated. Countries: 1. Publications: 12.
Acute Viral Hepatitis and Diabetes Mellitus
ClinicalTrials.gov study NCT00689546. IPD Sharing: Not stated. Countries: 1. Publications: 6.
The Role of FGL2-FcgammaRIIB Inhibitory Pathway in Human Viral Hepatitis
ClinicalTrials.gov study NCT01711164. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Treatment With Peginterferon Alfa-2a (40 KD) of Chronic Hepatitis B Patients, Who Have Failed Anti-viral Treatment
ClinicalTrials.gov study NCT00226382. IPD Sharing: Not stated. Countries: 1. Publications: 8.
Assessment of Patients With Hepatitis C Virus Related Liver Cirrhosis After Sustained Response to Direct Acting Anti Viral Drugs.
ClinicalTrials.gov study NCT03241823. IPD Sharing: UNDECIDED. Countries: 1. Publications: 5.
Viral Kinetics and Liver Gene Expression in Response to Ribavirin and Peginterferon Therapy of Chronic Hepatitis C
ClinicalTrials.gov study NCT00718172. IPD Sharing: Not stated. Countries: 1. Publications: 6.
Data from: Epidemiology of Hepatitis E Virus in China: results from the Third National Viral Hepatitis Prevalence Survey, 2005-2006
Open the record for dataset details and reuse information.
Data from: Risk factors for bloodborne viral hepatitis in healthcare workers of Pakistan: a population based case–control study
Open the record for dataset details and reuse information.
Data from: miR-122, small RNA annealing and sequence mutations alter the predicted structure of the Hepatitis C virus 5′ UTR RNA to stabilize and promote viral RNA accumulation
Annealing of the liver-specific microRNA, miR-122, to the Hepatitis C virus (HCV) 5′ UTR is required for efficient virus replication. By using siRNAs to pressure escape mutations, 30 replication-competent HCV genomes having nucleotide changes in the conserved 5′ untranslated region (UTR) were identified. In silico analysis predicted that miR-122 annealing induces canonical HCV genomic 5′ UTR RNA folding, and mutant 5′ UTR sequences that promoted miR-122-independent HCV replication favored the formation of the canonical RNA structure, even in the absence of miR-122. Additionally, some mutant viruses adapted to use the siRNA as a miR-122-mimic. We further demonstrate that small RNAs that anneal with perfect complementarity to the 5′ UTR stabilize and promote HCV genome accumulation. Thus, HCV genome stabilization and life-cycle promotion does not require the specific annealing pattern demonstrated for miR-122 nor 5′ end annealing or 3′ overhanging nucleotides. Replication promotion by perfect-match siRNAs was observed in Ago2 knockout cells revealing that other Ago isoforms can support HCV replication. At last, we present a model for miR-122 promotion of the HCV life cycle in which miRNA annealing to the 5′ UTR, in conjunction with any Ago isoform, modifies the 5′ UTR structure to stabilize the viral genome and promote HCV RNA accumulation.
ANEMIA DEVELOPING IN VIRAL HEPATITIS B AND C
<p>The prevalence and steady growth of liver diseases among the population is one of the urgent and serious problems of modern medicine.</p><p>Hepatitis V and C viruses are one of the most common parenterally transmitted infections today and remain the main cause of chronic liver diseases. Hepatitis is widespread in the working class of the population, that is, among people aged 30 to 50 years, especially among men more often than women, the infection is chronic in about 80% of patients, and the rate of development of liver disease in 15-20% of cases passes to the terminal stage in an average of 20 years. , moreover, the fact that chronic hepatitis occurs with clinical symptoms other than the liver means that this disease is not only a medical but also an important economic and social problem.</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.